Dose justification for DS-8201a, a HER2-targeted antibody-drug conjugate, for HER2-positive breast cancer: Observed clinical data and exposure-response analyses Meeting Abstract


Authors: Tamura, K.; Modi, S.; Tsurutani, J.; Takahashi, S.; Krop, I. E.; Iwata, H.; Wada, R.; Yin, O.; Garimella, T.; Sugihara, M.; Zhang, L.; Lee, C.; Yver, A.; Baselga, J.
Abstract Title: Dose justification for DS-8201a, a HER2-targeted antibody-drug conjugate, for HER2-positive breast cancer: Observed clinical data and exposure-response analyses
Meeting Title: 41st Annual San Antonio Breast Cancer Symposium (SABCS)
Journal Title: Cancer Research
Volume: 79
Issue: 4 Suppl.
Meeting Dates: 2018 Dec 4-10
Meeting Location: San Antonio, TX
ISSN: 0008-5472
Publisher: American Association for Cancer Research  
Date Published: 2019-02-01
Language: English
ACCESSION: WOS:000478677002278
DOI: 10.1158/1538-7445.Sabcs18-p6-17-10
PROVIDER: wos
Notes: Meeting Abstract: P6-17-10 -- Source: Wos
Altmetric Score
MSK Authors
  1. Shanu Modi
    144 Modi
  2. Jose T Baselga
    438 Baselga